

Total study population enrolled

N = 2733

Exclusions from safety population

N

%

Ineligible as a result of quality review

135

4.9

No information on moxifloxacin intake

3

0.1

Safety population

N = 2595 (100.0%)

Exclusions from efficacy population

N*

%

Lost to follow up

1

<0.1

Age <18 years

9

0.3

Only oral moxifloxacin treatment

13

0.5

No CAP diagnosis

170

6.6

Concomitant anti-infective treatment

296

11.4

Manual exclusion due to implausible data

1

<0.1

*Multiple responses

Efficacy population

N = 2152 (82.9%)